Jeff Albers and Kate Haviland (Brad Bahner Photography/PR Newswire)
January 5, 2022 10:12 AM EST
People

Blue­print­'s long­time CEO pre­pares to step down as biotech rev­els in new Ay­vak­it launch, pipeline ex­pan­sion

Max Gelman

Senior Editor

Af­ter a busy 2021 brought Blue­print Med­i­cines its fourth FDA ap­proval, the com­pa­ny is kick­ing off the new year with plans to shake up its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times